318 related articles for article (PubMed ID: 33192668)
1. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine.
Rodrigues-Amorim D; Olivares JM; Spuch C; Rivera-Baltanás T
Front Psychiatry; 2020; 11():554899. PubMed ID: 33192668
[TBL] [Abstract][Full Text] [Related]
2. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.
Pergolizzi JV; Raffa RB; Taylor R; Rodriguez G; Nalamachu S; Langley P
Pain Pract; 2013 Mar; 13(3):239-52. PubMed ID: 22716295
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Müller N; Schennach R; Riedel M; Möller HJ
Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine for the management of fibromyalgia syndrome.
Scholz BA; Hammonds CL; Boomershine CS
J Pain Res; 2009 Jul; 2():99-108. PubMed ID: 21197298
[TBL] [Abstract][Full Text] [Related]
5. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
[TBL] [Abstract][Full Text] [Related]
6. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.
Mancini M; Perna G; Rossi A; Petralia A
Expert Opin Pharmacother; 2010 May; 11(7):1167-81. PubMed ID: 20402555
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder.
Muscatello MRA; Zoccali RA; Pandolfo G; Mangano P; Lorusso S; Cedro C; Battaglia F; Spina E; Bruno A
Front Psychiatry; 2019; 10():772. PubMed ID: 31749717
[No Abstract] [Full Text] [Related]
8. Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence.
Viktrup L; Pangallo BA; Detke MJ; Zinner NR
Prim Care Companion J Clin Psychiatry; 2004; 6(2):65-73. PubMed ID: 15254599
[TBL] [Abstract][Full Text] [Related]
9. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
10. The role of duloxetine in the treatment of anxiety disorders.
De Berardis D; Serroni N; Carano A; Scali M; Valchera A; Campanella D; D'Albenzio A; Di Giuseppe B; Moschetta FS; Salerno RM; Ferro FM
Neuropsychiatr Dis Treat; 2008 Oct; 4(5):929-35. PubMed ID: 19183783
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.
Dell'osso B; Camuri G; Dobrea C; Buoli M; Serati M; Altamura AC
Clin Pract Epidemiol Ment Health; 2012; 8():120-5. PubMed ID: 23166563
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial.
Upadhyaya HP; Arnold LM; Alaka K; Qiao M; Williams D; Mehta R
Pediatr Rheumatol Online J; 2019 May; 17(1):27. PubMed ID: 31138224
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
15. New treatment options for fibromyalgia: critical appraisal of duloxetine.
Uçeyler N; Offenbächer M; Petzke F; Häuser W; Sommer C
Neuropsychiatr Dis Treat; 2008 Jun; 4(3):525-9. PubMed ID: 18830399
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine for the treatment of generalized anxiety disorder: a review.
Khan AY; Macaluso M
Neuropsychiatr Dis Treat; 2009; 5():23-31. PubMed ID: 19557096
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
